Nothing Special   »   [go: up one dir, main page]

BR112019024851A2 - agente para evitar ou tratar atrofia cerebral - Google Patents

agente para evitar ou tratar atrofia cerebral Download PDF

Info

Publication number
BR112019024851A2
BR112019024851A2 BR112019024851A BR112019024851A BR112019024851A2 BR 112019024851 A2 BR112019024851 A2 BR 112019024851A2 BR 112019024851 A BR112019024851 A BR 112019024851A BR 112019024851 A BR112019024851 A BR 112019024851A BR 112019024851 A2 BR112019024851 A2 BR 112019024851A2
Authority
BR
Brazil
Prior art keywords
cerebral atrophy
agent
prevent
treat cerebral
benzothiophen
Prior art date
Application number
BR112019024851A
Other languages
English (en)
Inventor
Kobayashi Hiroshi
Matsumoto Yoshihiko
Original Assignee
Fujifilm Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Toyama Chemical Co Ltd filed Critical Fujifilm Toyama Chemical Co Ltd
Publication of BR112019024851A2 publication Critical patent/BR112019024851A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a presente invenção refere-se a um fármaco que evita o progresso de doença de alzheimer e um método para evitar progresso de doença de alzheimer. 1-(3-(2-(1-benzotiofen-5-il)etóxi)propil)azetidin-3-ol ou um sal do mesmo tem um efeito de suprimir atrofia cerebral e é útil como um agente para evitar ou tratar atrofia cerebral. a atrofia cerebral observada em envelhecimento ou doenças neurodegenerativas pode ser evitada ou tratada por administrar 1-(3-(2-(1-benzotiofen-5-il)etóxi)propil)azetidin-3-ol ou um sal do mesmo.
BR112019024851A 2017-06-02 2018-06-01 agente para evitar ou tratar atrofia cerebral BR112019024851A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2017109885 2017-06-02
JP2017128472 2017-06-30
JP2017145100 2017-07-27
PCT/JP2018/021223 WO2018221729A1 (ja) 2017-06-02 2018-06-01 脳萎縮予防または治療剤

Publications (1)

Publication Number Publication Date
BR112019024851A2 true BR112019024851A2 (pt) 2020-06-09

Family

ID=64455855

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019024851A BR112019024851A2 (pt) 2017-06-02 2018-06-01 agente para evitar ou tratar atrofia cerebral

Country Status (15)

Country Link
US (1) US11951092B2 (pt)
EP (1) EP3632431A4 (pt)
JP (2) JP7282028B2 (pt)
KR (1) KR20190137936A (pt)
CN (3) CN110709078A (pt)
AU (1) AU2018276638B2 (pt)
BR (1) BR112019024851A2 (pt)
CA (1) CA3067453C (pt)
IL (1) IL270922A (pt)
MX (1) MX2019014310A (pt)
NZ (1) NZ759585A (pt)
RU (1) RU2759727C2 (pt)
SG (1) SG11201911512SA (pt)
WO (1) WO2018221729A1 (pt)
ZA (1) ZA201907973B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL270910B2 (en) 2017-06-02 2024-03-01 Fujifilm Toyama Chemical Co Ltd 1-(3-(2-(1-benzothiophene-5-yl)ethoxy)propyl)aztidine-3-ol or a salt thereof for use in suppressing cerebral atrophy
AU2018277983B2 (en) 2017-06-02 2021-04-08 Fujifilm Toyama Chemical Co., Ltd. Amyloid-β protein level decreasing agent
JPWO2018221728A1 (ja) 2017-06-02 2020-04-02 富士フイルム富山化学株式会社 アルツハイマー型認知症予防または治療剤
MX2019014310A (es) * 2017-06-02 2022-06-10 Fujifilm Toyama Chemical Co Ltd Agente para prevenir o tratar atrofia cerebral.
US11548878B2 (en) 2017-10-30 2023-01-10 Fujifilm Toyama Chemical Co., Ltd. Emopamil binding protein binding agent and use thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1019091A4 (en) 1997-09-05 2005-05-11 Human Genome Sciences Inc 50 SECRETED PROTEINS OF HUMAN ORIGIN
GB9824207D0 (en) 1998-11-04 1998-12-30 Zeneca Ltd Neurological disorders
KR100956990B1 (ko) 2001-10-19 2010-05-11 토야마 케미칼 컴퍼니 리미티드 알킬에테르유도체 또는 그 염
DK2389937T3 (en) 2002-06-14 2018-11-12 Toyama Chemical Co Ltd Medical composition to improve brain function
WO2004091605A1 (ja) 2003-04-17 2004-10-28 Toyama Chemical Co., Ltd. アルキルエーテル誘導体またはその塩を含有する網膜神経疾患の予防・治療剤
DK2011796T3 (da) 2006-04-26 2014-10-27 Toyama Chemical Co Ltd Neurogenese-inducer eller terapeutisk middel mod neuropati omfattende alkyletherderivat eller salt deraf
US8119625B2 (en) * 2006-04-26 2012-02-21 Toyama Chemical Co., Ltd. Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
US8450346B2 (en) 2008-03-04 2013-05-28 Vernalis (R&D) Ltd. Azetidine derivatives as FAAH inhibitors
FR2934596B1 (fr) 2008-07-30 2015-04-10 Trophos Nouveaux derives de l'oxime de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, et procede de preparation
EP2419104B1 (en) 2009-04-13 2017-11-08 Theravance Biopharma R&D IP, LLC Combinations of 5-ht4 receptor agonists and acetylcholinesterase inhibitors for treatment of cognitive disorders
MX2011011972A (es) 2009-05-11 2011-12-08 Envivo Pharmaceuticals Inc Tratamiento de trastornos cognitivos con determinados receptores de acido nicotinico alfa-7 en combinacion con inhibidores de acetilcolinesterasa.
WO2011057199A1 (en) 2009-11-06 2011-05-12 Adenios, Inc. Compositions for treating cns disorders
JP6054940B2 (ja) 2012-02-22 2016-12-27 富山化学工業株式会社 １−（３−（２−（１−ベンゾチオフェン−５−イル）エトキシ）プロピル）アゼチジン−３−オールまたはその塩を含有する固形医薬組成物
WO2014015157A2 (en) 2012-07-19 2014-01-23 Philadelphia Health & Education Corporation Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same
MX2015002398A (es) 2012-10-01 2015-06-05 Hoffmann La Roche Benzimidazoles como agentes activos del sistema nervioso central.
RS60462B1 (sr) 2014-01-31 2020-07-31 Fujifilm Toyama Chemical Co Ltd Sredstvo za poboljšanje rehabilitacionog efekta nakon oštećenja nerva, koje sadrži derivat alkil etra ili njegovu so
JP6165323B2 (ja) 2014-04-25 2017-07-19 レジリオ株式会社 アルツハイマー病の治療剤を含む、神経細胞の軸索の機能不全が関与する疾患の治療剤
WO2015188368A1 (en) 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles
WO2016051799A1 (ja) 2014-10-01 2016-04-07 学校法人同志社 ２－アミノヒドロキノン誘導体及びタウ凝集阻害剤
WO2016124508A1 (en) 2015-02-02 2016-08-11 Ucb Biopharma Sprl 9h-pyrrolo-dipyridine derivatives
US20160324851A1 (en) 2015-05-07 2016-11-10 Axovant Sciences, Ltd. Methods of treating a neurodegenerative disease
US10238632B2 (en) 2015-06-11 2019-03-26 Fujifilm Toyama Chemical Co., Ltd. Sigma receptor-binding agent
CN108366989B (zh) 2015-12-25 2020-11-03 富士胶片富山化学株式会社 含有1-(3-(2-(1-苯并噻吩-5-基-)乙氧基)丙基)氮杂环丁-3-醇或其盐的片剂
JPWO2018221728A1 (ja) 2017-06-02 2020-04-02 富士フイルム富山化学株式会社 アルツハイマー型認知症予防または治療剤
MX2019014310A (es) * 2017-06-02 2022-06-10 Fujifilm Toyama Chemical Co Ltd Agente para prevenir o tratar atrofia cerebral.
JP7370859B2 (ja) 2017-06-02 2023-10-30 富士フイルム富山化学株式会社 タウオパチー予防または治療剤
AU2018277983B2 (en) 2017-06-02 2021-04-08 Fujifilm Toyama Chemical Co., Ltd. Amyloid-β protein level decreasing agent
IL270910B2 (en) 2017-06-02 2024-03-01 Fujifilm Toyama Chemical Co Ltd 1-(3-(2-(1-benzothiophene-5-yl)ethoxy)propyl)aztidine-3-ol or a salt thereof for use in suppressing cerebral atrophy
US11548878B2 (en) 2017-10-30 2023-01-10 Fujifilm Toyama Chemical Co., Ltd. Emopamil binding protein binding agent and use thereof

Also Published As

Publication number Publication date
WO2018221729A1 (ja) 2018-12-06
US20200215030A1 (en) 2020-07-09
AU2018276638B2 (en) 2021-04-08
JP7282028B2 (ja) 2023-05-26
MX2019014310A (es) 2022-06-10
KR20190137936A (ko) 2019-12-11
NZ759585A (en) 2022-02-25
SG11201911512SA (en) 2020-01-30
IL270922A (en) 2020-01-30
ZA201907973B (en) 2022-03-30
CN116492335A (zh) 2023-07-28
JPWO2018221729A1 (ja) 2020-04-09
RU2759727C2 (ru) 2021-11-17
US11951092B2 (en) 2024-04-09
EP3632431A4 (en) 2020-06-03
CN110709078A (zh) 2020-01-17
CA3067453C (en) 2021-11-23
RU2019138166A (ru) 2021-07-09
EP3632431A1 (en) 2020-04-08
RU2019138166A3 (pt) 2021-07-09
CN116473962A (zh) 2023-07-25
AU2018276638A1 (en) 2019-12-19
JP2023053337A (ja) 2023-04-12
CA3067453A1 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
BR112019024851A2 (pt) agente para evitar ou tratar atrofia cerebral
BR112016000546A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
BR112019024878A2 (pt) Agente para prevenção ou tratamento de tauopatia
BR112017003546A2 (pt) amidas heterocíclicas como inibidores de rip1 quinase como medicamentos
MX2016014634A (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
BR112017008093A2 (pt) processos para tratamento de doenças oculares
MX2009011127A (es) Metodo de prevencion y tratamiento de angiopatia amiloide cerebral.
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
BR112017017078A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para prevenir, gerenciar, tratar ou amenizar uma doença.
CR20120638A (es) Métodos de terapia combinada para tratar enfermedades proliferativas
MX2022010274A (es) Uso de dexmedetomidina sublingual para el tratamiento de la agitacion.
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
BR112017028132A2 (pt) métodos de tratamento de malignidade hematológica usando terapia combinada de inibidor de mtor em nanopartícula
BR112015024530A2 (pt) composto, métodos para tratamentos de distúrbios e de doenças e para profilaxia de distúrbios, composição farmacêutica, e, uso de um composto
MX2014002459A (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos.
BR112015018438A2 (pt) anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento
MX2019003397A (es) Metodos para tratar trastornos mitocondriales y metabolicos.
PH12017502049A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EA201791993A1 (ru) Способы лечения протеинопатий
BR112015021334A2 (pt) formulações oculares para entrega de droga ao segmento posterior do olho
BR112015011213A2 (pt) Composto, composição farmacêutica, método de prevenção ou tratamento de um distúrbio ou doença de controle respiratório em um indivíduo, método de prevenção de desestabilização ou de estabilização do ritmo respiratório em um indivíduo, método de preparação de o,n-dimetil-n-[4-(n-propilamina)-6-(prop-2-inilamina)-[1,3,5]triazin-2-il]-hidroxilamina, e composição.
BR112019024881A2 (pt) Agente para evitar ou tratar ataxia espinocerebelar
BR112017013674A2 (pt) métodos e composições para tratamento de doenças cerebrais.
BR112015020963A2 (pt) derivado de 2-acilaminotiazola ou sal do mesmo
BR112019005985A2 (pt) composições de combinação compreendendo agonistas de fxr para tratar ou prevenir uma doença ou distúrbio fibrótico, cirrótico

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]